Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Daily alcohol intake, certain drugs tied to liver abnormalities in PsA patients

30 Jun 2020

Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.

A total of 1,061 patients were followed in a PsA clinic, of whom 343 had liver abnormalities. After the first visit, 256 patients developed liver abnormalities and were considered as cases, while 718 were identified as controls.

Liver abnormalities had a 32-percent prevalence, and the incidence stood at 39 per 1,000 patient-years where there were 256 cases over 6,533 total person-years in the PsA cohort. Detection of such defects occurred after a mean follow-up duration of 8.3±7.8 years.

Drug-induced hepatitis and fatty liver were the most common causes of liver abnormalities, while the independent factors associated with these defects included higher BMI, daily alcohol intake, higher damaged joint count, elevated C-reactive protein, and use of methotrexate, leflunomide, or tumour necrosis factor inhibitors.

The authors identified PsA patients with either elevated serum transaminase or alkaline phosphatase levels or liver disease after first visit to a PsA clinic from a longitudinal cohort study. They identified controls from the same cohort who never had liver abnormalities or disease.

Cases and controls were matched 1:1 by sex, age, at first clinic visit, and follow-up duration. Univariate logistic and multivariate logistic regression analyses were used to identify variables at the first appearance of liver test abnormality associated with liver conditions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.